A Prospective Cohort Study for Patients With Adrenal Diseases
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Mar 15, 2018
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The investigators will recruit 150 patients annually for 10 years (adrenal incidentaloma 100 patients, pheochromocytoma 15 patients, primary aldosteronism 25 patients, adrenal cushing syndrome 10 patients, adrenocortical carcinoma 2 patients) and perform hormonal, biochemical, imaging exam according to each disease's clinical guidelines. Based on this, the investigators will identify pathologic features, complications, and prognostic factors of each disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults, male or female aged 19 years or older
- • newly diagnosed with adrenal disease such as adrenal incidentaloma, pheochromocytoma, primary aldosteronism, adrenal cushing syndrome, adrenocortical carcinoma
- Exclusion Criteria:
- • previous or current history of adrenal diseases
- • using oral or intravenous steroids
- • history of major depressive disorder
- • history of chronic alcoholics
- • history of any cancer with suspicious adrenal metastasis
- • those with acute illness (ex- patients with acute coronary syndrome within 4 weeks, acute febrile disease)
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Jung Hee Kim, M.D
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials